Lee et al. injected hyperglycemic mice with human recombinant FGF21 from Sino Biological to study the synergistic effect of FOXO1 inhibition and FGF21 in lowering glucose levels in diabetic mice.

Apollo Therapeutics Group Ltd. and Sunshine Lake Pharma Co. Ltd. inked a potential $938 million licensing deal for APL-18881 (HEC-88473), Sunshine’s dual fibroblast growth factor 21 ...

is a once-monthly subcutaneous injectable of a long-acting variant of human fibroblast growth factor 21 (FGF21) that regulates various metabolic pathways to decrease liver fat and ameliorate liver ...